A considerable proportion of non-small-cell lung cancer (NSCLC) patients will develop
central nervous system (CNS) metastases throughout the course of their disease and these …

Purpose Brain metastasis (BM) is a leading cause of death from non–small-cell lung cancer
(NSCLC). Reasoning that activation of the epidermal growth factor receptor (EGFR) …

Opinion statement Management of non-small cell lung cancer (NSCLC) with brain
metastasis (BrM) has been revolutionized by identification of molecular subsets that have …

Introduction: Brain metastases (BM) are a common and lethal complication of non-small cell
lung cancer (NSCLC) with up to 40% experiencing this complication. The use of erlotinib, a …

Brain parenchymal metastasis from a solid tumor is a serious clinical condition associated
with a poor outcome because systemic chemotherapy is usually ineffective for treating brain …

Non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor
receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase …

A small subset of patients with nonsmall cell lung cancer (NSCLC) harbors mutations in the
epidermal growth factor receptor (EGFR) that predict unique sensitivity to EGFR tyrosine …

Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …

Background There are many controversies concerning the best management of epidermal
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with …

Brain metastases (BM) are common and disastrous occurrence in patients with non-small
cell lung cancer (NSCLC). Currently increasing studies suggest remarkable efficacy and …